{"disease":{"id":"prevention-of-covid-19-in-individuals-12-years-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine-after-completion-of-primary-vaccination-with-any-covid-19-vaccine-when-administered-at-least-2-months-after-the-completion-of-primary-vaccination-or-any-subsequent-booster-dose-with-any-covid-19-vaccine-and-at-least-2-months-after-administration-of-a-prior-booster-dose-with-any-covid-19-vaccine.md","name":"prevention of covid 19 in individuals 12 years of age and older when administered as a booster dose in a series of the pfizer biontech covid 19 vaccine after completion of primary vaccination with any covid 19 vaccine when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any covid 19 vaccine and at least 2 months after administration of a prior booster dose with any covid 19 vaccine.md"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}